Ascendis Pharma A/S (ASND)
- Previous Close
140.89 - Open
141.39 - Bid 139.92 x 100
- Ask 140.58 x 100
- Day's Range
137.78 - 144.41 - 52 Week Range
66.03 - 161.00 - Volume
267,109 - Avg. Volume
355,500 - Market Cap (intraday)
7.936B - Beta (5Y Monthly) 0.51
- PE Ratio (TTM)
-- - EPS (TTM)
-9.13 - Earnings Date Apr 25, 2024 - Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.29
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ascendispharma.comRecent News: ASND
Performance Overview: ASND
Trailing total returns as of 4/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ASND
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ASND
Valuation Measures
Market Cap
7.94B
Enterprise Value
8.20B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.73
Price/Book (mrq)
--
Enterprise Value/Revenue
30.73
Enterprise Value/EBITDA
-19.94
Financial Highlights
Profitability and Income Statement
Profit Margin
-180.51%
Return on Assets (ttm)
-29.73%
Return on Equity (ttm)
-818.43%
Revenue (ttm)
266.72M
Net Income Avi to Common (ttm)
-481.45M
Diluted EPS (ttm)
-9.13
Balance Sheet and Cash Flow
Total Cash (mrq)
399.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-318.3M
Research Analysis: ASND
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell